Latest news
25 items- PRTotus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial OfficerEMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said
- 13D/GSEC Form SC 13G/A filed by Calyxt Inc. (Amendment)SC 13G/A - Cibus, Inc. (0001705843) (Subject)
- SECCalyxt Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Cibus, Inc. (0001705843) (Filer)
- INSIDERRiggs Rory B converted options into 1,500,000 shares and acquired 1,505,967 units of Class B Common Stock, increasing direct ownership by 128% to 3,103,788 units (SEC Form 4)4 - Cibus, Inc. (0001705843) (Issuer)
- SECCalyxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Cibus, Inc. (0001705843) (Filer)
- SECSEC Form 424B5 filed by Calyxt Inc.424B5 - Cibus, Inc. (0001705843) (Filer)
- SECCalyxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Cibus, Inc. (0001705843) (Filer)
- INSIDERRiggs Rory B disposed of 39,476 shares and bought $5,470,992 worth of shares (517,107 units at $10.58), increasing direct ownership by 47% to 1,622,495 units (SEC Form 4)4 - Cibus, Inc. (0001705843) (Issuer)
- SECCalyxt Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Cibus, Inc. (0001705843) (Filer)
- SECSEC Form 424B5 filed by Calyxt Inc.424B5 - Cibus, Inc. (0001705843) (Filer)
- SECCalyxt Inc. filed SEC Form 8-K: Other Events8-K - Cibus, Inc. (0001705843) (Filer)
- SECSEC Form 424B5 filed by Calyxt Inc.424B5 - Cibus, Inc. (0001705843) (Filer)
- SECCalyxt Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Cibus, Inc. (0001705843) (Filer)
- SECSEC Form 10-Q filed by Calyxt Inc.10-Q - Cibus, Inc. (0001705843) (Filer)
- SECCalyxt Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Cibus, Inc. (0001705843) (Filer)
- SECCalyxt Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cibus, Inc. (0001705843) (Filer)
- SECSEC Form 424B3 filed by Calyxt Inc.424B3 - Cibus, Inc. (0001705843) (Filer)
- SECSEC Form EFFECT filed by Calyxt Inc.EFFECT - Cibus, Inc. (0001705843) (Filer)
- SECSEC Form S-3/A filed by Calyxt Inc. (Amendment)S-3/A - Cibus, Inc. (0001705843) (Filer)
- SECCalyxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - Cibus, Inc. (0001705843) (Filer)
- SECCalyxt Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Other Events, Leadership Update8-K - Cibus, Inc. (0001705843) (Filer)
- INSIDERSEC Form 3: New insider Collins James C. Jr. claimed no ownership of stock in the company3 - Cibus, Inc. (0001705843) (Issuer)
- SECCalyxt Inc. filed SEC Form 8-K: Leadership Update8-K - Cibus, Inc. (0001705843) (Filer)
- SECCalyxt Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Cibus, Inc. (0001705843) (Filer)
- SECSEC Form 10-Q filed by Calyxt Inc.10-Q - Cibus, Inc. (0001705843) (Filer)
CLXT FAQ
7 questionsWhat does Calyxt Inc. do?
Calyxt, Inc., a technology company, focuses on delivering plant-based solutions in the United States. It engages in the development of improved digestibility alfalfa; high fiber wheat; high oleic low linolenic soybeans; winter oats; hemp; fat soybeans; and cold storable potatoes. As of March 4, 2021, the company had nine projects at Phase I stage or later in development across alfalfa, hemp, oats, soybeans, and wheat. Calyxt, Inc. has a research collaboration with NRGene, which includes the adoption of NRGene's cloud-based genomics platform to support various research projects; and a...Where does CLXT stock trade?
Calyxt Inc. (CLXT) is listed on NASDAQ.What sector and industry is CLXT in?
Calyxt Inc. operates in the Industrials sector, Agricultural Chemicals industry.When did Calyxt Inc. go public?
Calyxt Inc. (CLXT) completed its IPO in 2017.What are analysts saying about CLXT?
Calyxt Inc. has had 2 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy with a $400.00 price target on 2022-03-04. Recent price targets range from $400.00 to $1000.00.What companies are similar to CLXT?
Notable peers in the same industry include NTR (Nutrien Ltd.), CF (CF Industries Holdings Inc.), ICL (ICL Group Ltd.), MOS (Mosaic Company), SMG (Scotts Miracle-Gro Company). Compare CLXT side-by-side with any of them on Quantisnow.How can I track CLXT on Quantisnow?
Quantisnow aggregates Calyxt Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CLXT to receive live email and push alerts on every new disclosure.